Detection of MRD in TNBC Through Multi-Platform Molecular Biomarker Analysis
通过多平台分子生物标志物分析检测 TNBC 中的 MRD
基本信息
- 批准号:10580880
- 负责人:
- 金额:$ 12.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-18 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdjuvantAdjuvant TherapyBiological MarkersBiologyBreast Cancer PatientCenters of Research ExcellenceClinical TrialsDNA analysisDetectionDiseaseFundingGoalsHeterogeneityIndividualIndustryInstitutesKansasMissionMolecularNeoadjuvant TherapyNeoplasm Circulating CellsPatientsPerceptionPlasmaRandomizedResearchResearch PersonnelResidual NeoplasmResidual TumorsSystemic TherapyTumor BiologyUntranslated RNAWorkbaseextracellular vesicleshigh riskimprovedindividual variationindividualized medicinemolecular markerprecision medicineprognosticprogramsprospectiverelapse riskrisk stratificationstandard of caretreatment optimizationtriple-negative invasive breast carcinomatumor DNAwillingness
项目摘要
The overarching goal of our research program is to understand the molecular heterogeneity of triple-negative
breast cancer (TNBC), to identify and validate biomarkers that are both prognostic and predictive,
and ultimately to optimize treatment for each patient based on the biology of her/his tumor. Towards this
end, we have recently received funding to conduct a prospective investigator-initiated clinical trial entitled
Adjuvant Intensification for Minimal Residual Disease in Triple-Negative Breast Cancer (AIM-TNBC) that is
evaluating intensification of adjuvant systemic therapy in TNBC patients with residual disease after
neoadjuvant systemic therapy. With industry support from Natera, Inc., we will use personalized circulating
tumor DNA (ctDNA) analysis to identify patients with minimal residual disease and then randomize these
high-risk patients to standard-of-care versus intensified adjuvant therapy. Our specific aims for this KIPM
COBRE application are (1) to evaluate circulating tumor cells (CTCs) and non-coding RNAs
(ncRNAs) in plasma-derived extracellular vesicles (EVs) as additional biomarkers of minimal
residual disease to define a high-risk MRD signature in our prospective AIM-TNBC trial and (2) to
understand how molecular biomarker information influences TNBC patients’ perception of
individual relapse risk and willingness to accept adjuvant therapy. This work will ultimately improve
our ability to risk-stratify TNBC patients and identify those who are likely to benefit from intensification of
adjuvant systemic therapy. This goal is aligned with the KIPM COBRE’s mission of providing precision
medicine in that it considers individual variability in the molecular composition of one’s disease and aims to
tailor treatment towards each patient’s unique biology.
我们研究计划的总体目标是了解三阴性的分子异质性
乳腺癌(TNBC),识别和验证具有预后和预测作用的生物标志物,
最终根据每位患者的肿瘤生物学特性优化治疗方案。朝这个方向
最后,我们最近收到了资金来进行一项由研究者发起的前瞻性临床试验,题为
三阴性乳腺癌微小残留病 (AIM-TNBC) 的辅助强化治疗
评估术后残留病灶的 TNBC 患者强化辅助全身治疗
新辅助全身治疗。在 Natera, Inc. 的行业支持下,我们将使用个性化流通
肿瘤 DNA (ctDNA) 分析可识别具有微小残留病的患者,然后对这些患者进行随机分组
高危患者接受标准护理与强化辅助治疗。我们本次 KIPM 的具体目标
COBRE 应用是 (1) 评估循环肿瘤细胞 (CTC) 和非编码 RNA
血浆来源的细胞外囊泡(EV)中的(ncRNA)作为最小的额外生物标志物
在我们的前瞻性 AIM-TNBC 试验中定义高风险 MRD 特征的残留疾病,以及 (2)
了解分子生物标志物信息如何影响 TNBC 患者的认知
个体复发风险和接受辅助治疗的意愿。这项工作最终将得到改善
我们有能力对 TNBC 患者进行风险分层并确定那些可能从强化治疗中受益的患者
辅助全身治疗。这一目标与 KIPM COBRE 的使命是一致的:提供精确的
医学的特点是它考虑了疾病分子组成的个体差异,旨在
根据每位患者独特的生物学特征制定治疗方案。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven Allan Soper其他文献
Steven Allan Soper的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven Allan Soper', 18)}}的其他基金
Using integrated omics to identify dysfunctional genetic mechanisms influencing schizophrenia and sleep disturbances
使用整合组学来识别影响精神分裂症和睡眠障碍的功能失调的遗传机制
- 批准号:
10770880 - 财政年份:2023
- 资助金额:
$ 12.16万 - 项目类别:
Sense-of-Scale: The use of mixed-scale systems for rare biomarker analysis
规模感:使用混合规模系统进行稀有生物标志物分析
- 批准号:
10493147 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
Biotechnology Resource Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine
精准医学生物模块化多尺度系统(CBM2)生物技术资源中心
- 批准号:
10693387 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
Biotechnology Resource Center of BioModular Multi-scale Systems (CBM2) for Precision Medicine
精准医学生物模块化多尺度系统(CBM2)生物技术资源中心
- 批准号:
10493122 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
Single-Molecule Processing: Detection and Identification of Single DNAs, RNAs, and Proteins using Immobilized Nanoscale Enzymatic Reactors (INERs) and Nanoscale Electrophoresis
单分子处理:使用固定化纳米级酶反应器 (INER) 和纳米级电泳检测和鉴定单个 DNA、RNA 和蛋白质
- 批准号:
10493128 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
Biotechnology Resource Center of Biomodular Multi scale Systems CBM2 for Precision Molecular Diagnostics
用于精密分子诊断的生物模块化多尺度系统 CBM2 生物技术资源中心
- 批准号:
9404585 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
Biotechnology Resource Center of Biomodular Multi scale Systems CBM2 for Precision Molecular Diagnostics
用于精密分子诊断的生物模块化多尺度系统 CBM2 生物技术资源中心
- 批准号:
8935077 - 财政年份:2015
- 资助金额:
$ 12.16万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 12.16万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 12.16万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 12.16万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 12.16万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 12.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 12.16万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 12.16万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 12.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 12.16万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 12.16万 - 项目类别:
Operating Grants